Compare iShares MSCI Canada (TSX) (EWC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI Canada (TSX) trades at $61.82, while IDEXX Laboratories, Inc. trades at $588.36 (market cap $46.22B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| EWC | IDXX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $766.68 |
52-Week Low | $47.00 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $61.72, up 0.35% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF remains focused on Canadian equities, showing double-digit returns in 2026 but trailing the S&P 500. Recent news highlights trade tensions with the U.S., including potential 50% tariffs on Canadian goods, though key sectors like energy are exempt.
Outlook is mixed: bullish technicals and strong 2026 performance support upside, but trade war risks and overbought conditions pose near-term headwinds. Investors should weigh Canada's economic resilience against tariff uncertainties for balanced exposure.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
